Skip to content

ClearPoint Neuro CLPT Free cash flow

Free cash flow at other companies

Abbott logo
AbbottABT
$916M-1.8%
Boston Scientific logo
Boston ScientificBSX
$171M-51.7%
IAR
Integra LifeSciencesIART
-$5.05M+87.4%
Medtronic logo
MedtronicMDT
$2.09B+0.8%
Neuropace, Inc. logo
Neuropace, Inc.NPCE
-$6.02M+20.0%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH

Other financials

Income statement

See full
Revenue$12.1M+42.9%
Gross profit$7.8M+51.1%
Operating income-$8.5M-37.6%
Net income-$9.6M-58.5%
EPS (diluted)-$0.32-45.5%

Balance sheet

See full
Cash & equivalents$36.5M+195%
Total debt$63.6M+1,750%
Total equity$18.8M-5.7%
Total assets$93.4M+211%

Cash flow

See full
Operating cash flow-$8.0M-29.1%
CapEx$645.0K+252%

Valuation

See full
Market cap$538.61M+69.2%
Enterprise value$565.68M+82.9%
P/S13.3×+3.4×

Profitability

See full
Gross margin62.3%+1.1pp
Operating margin-65.2%-1.9pp
Net margin-71.6%+8.8pp
FCF margin-65.7%+269pp

Returns & leverage

See full
Return on equity-149.7%+4,074pp
Debt / equity3.4×+3.2×
Current ratio5.8×+2.3×

Where this comes from

Calculated from ClearPoint Neuro’s reported figures.

The official record: ClearPoint Neuro’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about ClearPoint Neuro's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ClearPoint Neuro's free cash flow?
ClearPoint Neuro (CLPT) reported free cash flow of -$8.61M in Q1 2026.
How has ClearPoint Neuro's free cash flow changed year-over-year?
ClearPoint Neuro's free cash flow decreased by 35.5% year-over-year, from -$6.36M to -$8.61M.
What is the long-term trend for ClearPoint Neuro's free cash flow?
Over 4 years (2021 to 2025), ClearPoint Neuro's free cash flow has grown at a 17.4% compound annual growth rate (CAGR), from -$12.87M to -$24.42M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.